Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Drug Discov Technol ; 20(3): e090323214492, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36892116

RESUMO

BACKGROUND: Diabetes occurs due to insulin deficiency or less insulin. To manage this condition, insulin administration as well as increased insulin sensitivity is required, but exogeneous insulin cannot replace the sensitive and gentle regulation of blood glucose levels same as ß cells of healthy individuals. By considering the ability of regeneration and differentiation of stem cells, the current study planned to evaluate the effect of metformin preconditioned buccal fat pad (BFP) derived mesenchymal stem cells (MSCs) on streptozotocin (STZ) induced diabetes mellitus in Wistar rats. MATERIALS & METHODS: The disease condition was established by using a diabetes-inducing agent STZ in Wistar rats. Then, the animals were grouped into disease control, blank, and test groups. Only the test group received the metformin-preconditioned cells. The total study period for this experiment was 33 days. During this period, the animals were monitored for blood glucose level, body weight, and food-water intake twice a week. At the end of 33 days, the biochemical estimations for serum insulin level and pancreatic insulin level were performed. Also, histopathology of the pancreas, liver and skeletal muscle was performed. RESULTS: The test groups showed a decline in the blood glucose level and an increase in the serum pancreatic insulin level as compared to the disease group. No significant change in food and water intake was observed within the three groups, while body weight was significantly reduced in the test group when compared with the blank group, but the life span was increased when compared with the disease group. CONCLUSION: In the present study, we concluded that metformin preconditioned buccal fat pad-derived mesenchymal stem cells have the ability to regenerate damaged pancreatic ß cells and have antidiabetic activity, and this therapy is a better choice for future research.


Assuntos
Diabetes Mellitus Experimental , Células-Tronco Mesenquimais , Metformina , Ratos , Animais , Metformina/farmacologia , Metformina/uso terapêutico , Ratos Wistar , Glicemia , Células-Tronco Mesenquimais/patologia , Insulina/uso terapêutico , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/patologia , Peso Corporal
2.
Curr Diabetes Rev ; 19(5): e110422203402, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-35410613

RESUMO

Type 1 diabetes mellitus (T1DM), an autoimmune disease, involves the destruction of pancreatic ß cells. ß cells maintain glucose homeostasis by identifying blood glucose and accordingly releasing insulin to maintain normal physiologic glucose levels. Human umbilical cord blood (hUCB) cells pose a lesser risk of viral contamination due to low placental transmission during prenatal life. Additionally, they have advantages such as non-invasive harvest procedure gynecological waste, low immunogenicity, easy expansion in-vitro, and easy ethical access compared to deriving stem cells from other sources. According to the published preclinical data, the infusion of autologous cord blood cells is considered safe as they are non-antigenic. Depending on the degree of differentiation, the ability to regenerate themselves and the origin of many stem cell types can be differentiated. The application of stem cells (SCs) has great potential for managing T1DM due to their regenerative capabilities and promising immunological characteristics. Due to lesser ethical complications and easy procedures of isolation, hUCB has become a precious medical intervention.


Assuntos
Diabetes Mellitus Tipo 1 , Gravidez , Humanos , Feminino , Diabetes Mellitus Tipo 1/terapia , Placenta , Insulina , Células-Tronco , Glicemia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...